769 related articles for article (PubMed ID: 11172948)
1. Optimizing patient selection for prostate monotherapy.
Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
[TBL] [Abstract][Full Text] [Related]
2. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.
D'Amico AV; Renshaw AA; Schultz D; Rocha S; Richie JP
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):847-51. PubMed ID: 10571188
[TBL] [Abstract][Full Text] [Related]
3. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
4. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy.
D'Amico AV; Renshaw AA; Arsenault L; Schultz D; Richie JP
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):841-6. PubMed ID: 10571187
[TBL] [Abstract][Full Text] [Related]
5. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Renshaw AA; Tomaszewski JE; Richie JP; Wein A
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1227-33. PubMed ID: 10613317
[TBL] [Abstract][Full Text] [Related]
6. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
Caster JM; Falchook AD; Hendrix LH; Chen RC
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
[TBL] [Abstract][Full Text] [Related]
7. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.
Grossfeld GD; Latini DM; Lubeck DP; Broering JM; Li YP; Mehta SS; Carroll PR
Urology; 2002 Apr; 59(4):560-5. PubMed ID: 11927314
[TBL] [Abstract][Full Text] [Related]
8. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
9. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer.
D'Amico AV; Schultz D; Silver B; Henry L; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):679-84. PubMed ID: 11172949
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Silver B; Henry L; Hurwitz M; Kaplan I; Beard CJ; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
Mol Urol; 2000; 4(3):171-5;discussion 177. PubMed ID: 11062371
[TBL] [Abstract][Full Text] [Related]
11. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
King CR; McNeal JE; Gill H; Presti JC
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
[TBL] [Abstract][Full Text] [Related]
12. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
13. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml.
D'Amico AV; Whittington R; Kaplan I; Beard C; Jiroutek M; Malkowicz SB; Wein A; Coleman CN
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1053-8. PubMed ID: 9169812
[TBL] [Abstract][Full Text] [Related]
14. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
15. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
16. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
[TBL] [Abstract][Full Text] [Related]
17. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
18. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.
Gancarczyk KJ; Wu H; McLeod DG; Kane C; Kusuda L; Lance R; Herring J; Foley J; Baldwin D; Bishoff JT; Soderdahl D; Moul JW
Urology; 2003 Mar; 61(3):589-95. PubMed ID: 12639653
[TBL] [Abstract][Full Text] [Related]
19. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.
Krane LS; Menon M; Kaul SA; Siddiqui SA; Wambi C; Peabody JO; Agarwal PK
Urol Oncol; 2011; 29(4):372-7. PubMed ID: 19576796
[TBL] [Abstract][Full Text] [Related]
20. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.
Grossfeld GD; Latini DM; Lubeck DP; Mehta SS; Carroll PR
J Urol; 2003 Jan; 169(1):157-63. PubMed ID: 12478126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
